EVOK

Evoke Pharma Inc

EVOK, USA

Evoke Pharma, Inc. operates as a specialty pharmaceutical company that focuses on the development and commercialization of drugs for the treatment of gastroenterological disorders and diseases. It offers Gimoti, a metoclopramide nasal spray to treat symptoms associated with acute and recurrent diabetic gastroparesis in adults. The company markets its products to gastroenterologists, internal medicine specialists, primary care physicians, and select health care providers. Evoke Pharma, Inc. was incorporated in 2007 and is based in Solana Beach, California.

https://www.evokepharma.com

Stock Price

$0.00

0%

decrease compared to yesterday.

Dividend

Frequency:

N/A

Rate:

N/A

Next Payout:

N/A
EVOK
stock
EVOK

Will EVOK stock remain a Wall Street favorite - Geopolitical Risk Analysis & Free Discover Breakout Stocks Early bollywoodhelpline.com

Read more →
EVOK
stock
EVOK

Will K s Holdings Corporation (KSD) stock remain on Wall Street radar - Quarterly Performance Summary & Long-Term Growth Stock Strategies bollywoodhelpline.com

Read more →

Showing 2 of 10

Analyst Ratings & Sentiment

(Last Updated 2025-09-30)

Rating:

BUY

Target Price:

$18

Analyst Picks

Strong Buy

0

Buy

1

Hold

0

Sell

0

Strong Sell

0

Sentiment:

Bullish

Finn Analysis

(Last Updated 2025-09-30)

Health Score

Price to Book Ratio (P/B)

-

Very High

17.00

Low ≤ 1

High ≥ 3

Return on Equity (ROE)

-

Very Low

-34.39 %

Low ≤ 5%

High ≥ 25%

Return on Assets (ROA)

-

Very Low

-7.39 %

Low ≤ 2%

High ≥ 10%

Free Cash Flow - Revenue % (FCF)

-

Very Low

-12.18 %

Low ≤ 5%

High ≥ 15%

Debt to Equity

-

Very Low

3.65

Low ≥ 1

High ≤ 0.3

Investors

* Institutions hold a combined 15.59% of the total shares of Evoke Pharma Inc

1.

Nantahala Capital Management, LLC

(9.5063%)

since

2025/06/30

2.

Bleichroeder LP

(4.4114%)

since

2025/06/30

3.

Citadel Advisors Llc

(0.8048%)

since

2025/06/30

4.

Fidelity Extended Market Index

(0.4081%)

since

2025/07/31

5.

Tower Research Capital LLC

(0.1276%)

since

2025/06/30

6.

Vanguard Institutional Extnd Mkt Idx Tr

(0.1097%)

since

2025/07/31

7.

Fidelity Series Total Market Index

(0.095%)

since

2025/07/31

8.

Spartan Total Market Index Pool G

(0.0333%)

since

2025/07/31

9.

FMR Inc

(0.0193%)

since

2025/06/30

10.

Northern Trust Extended Eq Market Idx

(0.0108%)

since

2025/06/30

11.

NT Ext Equity Mkt Idx Fd - L

(0.0108%)

since

2025/06/30

12.

BlackRock Inc

(0.0078%)

since

2025/06/30

13.

NT Ext Equity Mkt Idx Fd - NL

(0.0065%)

since

2025/06/30

14.

NT Ext Equity Mkt Idx Fd - DC - NL - T2

(0.005%)

since

2025/06/30

15.

SBI Securities Co Ltd

(0.0048%)

since

2025/06/30

16.

Morgan Stanley - Brokerage Accounts

(0.0041%)

since

2025/06/30

17.

State St US Extended Mkt Indx NL Cl C

(0.0035%)

since

2025/08/31

18.

NT Ext Eq Mkt Indx Fd DC Lending Tier 5

(0.003%)

since

2025/06/30

19.

BNYM Mellon SL Market Completion UC1

(0.003%)

since

2025/06/30

20.

Spartan Extended Market Index Pool F

(0.0029%)

since

2025/07/31

21.

Fidelity Total Market Index

(0.0026%)

since

2025/07/31

22.

NT Ext Eq Mkt Indx Fd DC Lend T3

(0.0026%)

since

2024/12/31

23.

SSgA U.S. Total Market Index Strategy

(0.0015%)

since

2025/03/31

24.

Northern Trust Wilshire 5000

(0.0012%)

since

2025/06/30

25.

Goss Wealth Management LLC

(0.0011%)

since

2025/06/30

26.

Bank of America Corp

(0.0006%)

since

2025/06/30

27.

UBS Group AG

(0%)

since

2025/03/31

* Investors data is estimated based on stocks listed on Finnton that are currently held by Institution/Fund.

Earnings History

EPS ActualEPS EstimateEPS DifferenceSurprise Percent

Upcoming Earnings Release

Date

—

EPS Estimate

—

Latest Release

Date

2025-09-30

EPS Actual

-0.45

EPS Estimate

-0.45

EPS Difference

0

Surprise Percent

0%

Investing Fit Scorecard

(Last Updated 2025-09-30)

Deep Value
Potential Value Candidate(3.5)
Defensive
Moderately Defensive(5.5)
Dividend
Weak Dividend Profile(1.5)
Economic Moat
Some Competitive Advantage(3.3)
GARP
Not Attractive for GARP(2)
Growth
Weak Growth Prospect(2)
Momentum
No Momentum(2.5)
Net Net
Not Undervalued (Net-Net)(2)
Quality
Low Quality Business(1.5)
Value
Overpriced(2)

Income Statement

(Last Updated 2025-09-30)

Revenue

$ 0

Cost Of Revenue

$ 0

Gross Profit

$ 0

Operating Expenses

$ 0

Operating Income

$ 0

Interest Expense

$ 0

Pretax Income

$ 0

Net Income

$ 0

Income Tax Expense

$ 0

EBITDA

$ 0

Total Other Income Expense Net

$ 0

Earnings Per Share

0

Dividends Per Share

0

Shares Outstanding

0

Operating Margin

0%

Trend

Balance Sheet

(Last Updated 2025-09-30)

Cash

$ 0

Short Term Investments

$ 0

Receivables

$ 0

Inventories

$ 0

Total Current Assets

$ 0

Property Plant Equipment

$ 0

Total Assets

$ 0

Payables

$ 0

Short Term Debt

$ 0

Long Term Debt

$ 0

Total Liabilities

$ 0

Equity

$ 0

Trend

Cash Flow

(Last Updated 2025-09-30)

Net Income

$ 0

Depreciation

$ 0

Change In Working Capital

$ 0

Cash From Operations

$ 0

Capital Expenditures

$ 0

Cash From Investing

$ 0

Cash From Financing

$ 0

Net Change In Cash

$ 0

Trend

Disclaimer: Finnton is a stock screener tool provided for informational and educational purposes only. The data, analysis, and insights offered on this website do not constitute financial, investment, tax, or legal advice. Users are solely responsible for their own investment decisions, and Finnton makes no guarantees regarding the accuracy, completeness, or reliability of the information provided. Past performance is not indicative of future results. Always conduct your own research and consult with a licensed financial advisor before making any investment decisions.